替格瑞洛所致呼吸困难与血浆中替格瑞洛和腺苷浓度的相关性

《替格瑞洛所致呼吸困难与血浆中替格瑞洛和腺苷浓度的相关性》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号16197中国图书分类号R9HebeiMedicalUniversity硕士学位论文学术学位替格瑞洛所致呼吸困难与血浆中替格瑞洛和腺苷浓度的相关性研究生：宋娟导师：杨秀岭主任药师专业：药物分析二级学院：河北医科大学第二医院2018年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师（或指导小组）的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单位河北医科大学，试

2、验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：导师签章：二级学院领导盖章：年月日河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果，指导教师对此进行了审定。本论文由本人独立撰写，文责自负。研究生签名：导师签章：年月日目录中文摘要···············································································

3、·····················1英文摘要····································································································4研究论文替格瑞洛所致呼吸困难与血浆中替格瑞洛和腺苷浓度的相关性引言····································································································7第一部分LC-MS/MS法同

4、时测定人血浆中替格瑞洛和腺苷的浓度前言····································································································9材料与方法························································································9结果···························································

5、·········································12附图····································································································15附表····································································································18讨论······················

6、··············································································21小结····································································································21参考文献·······················································································

7、·21第二部分替格瑞洛所致呼吸困难与血浆中替格瑞洛及腺苷浓度相关性前言····································································································23对象与方法························································································23结果·········································

8、···························································25附表············